Dyadic advances collaboration with israel institute for biological research (iibr) targeting bio-threats and emerging disease solutions

Jupiter, fla. and nes-ziona, israel, feb. 23, 2024 (globe newswire) -- dyadic international, inc. ("dyadic" or the "company") (nasdaq: dyai), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and israel institute for biological research (iibr) announced it has advanced its collaboration with the israel institute for biological research (iibr) and its commercial arm life science research israel (lsri), to target emerging disease solutions. this partnership aims to leverage dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the iibr's antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.
DYAI Ratings Summary
DYAI Quant Ranking